To date, atRA [16] and synthetic RAR agonists [40] have been reported to alleviate NAFLD in preclinical studies; however, little research has focused on regulating RARα expression and RARα-mediated transcriptional cascade for the treatment of NASH. The gene discussed is RARA; the disease is metabolic dysfunction-associated steatotic liver disease.